April 2008, Belfast

BHIVA 14th Annual Conference

Belfast Waterfront Hall

BHIVA 14th Annual Conference

• 500 delegates• 200 Poster presentations• 30 oral abstracts• 10 Satellite symposiums• 5 Plenary sessions• 3 big workshops• Presentation of awards for 3 best abstracts of

the conference by the Mayor of Belfast.

Relevant abstracts

• Immunotherapy while delaying HAART• 350 CD4 threshold for starting therapy• Protease Inhibitors monotherapy• Diagnosing the undiagnosed• Ageing of the PLH population• HIV treatment adherence for adolescents• Community HIV treatment adherence support • The importance of home delivery for ARVs

Diagnosing the undiagnosed

• Targeted prevention– Communities– Primary Care HIV testing

• Background– CDC – routine testing of 13-64 olds to reduce late

presentations

• Methods– Past diagnosed prevalence for MSM and HS

MSM - 0.25% prevalence and black women 2%

Diagnosing the undiagnosed

• Conclusion– Localised approach of targeting offers HIV

testing based on simple risk assessments.

– It allows local patient acceptability, setting appropriateness and partner notification.

Protease Inhibitors mono-therapyThe KIMODO Study

• Kaletra (Lopinavir + Ritonavir) monotherapy

• Kaletra + Sustiva/Neviralpine

• No significant difference between the two

• Benefits– Less toxicity– Better adherence– Better resistance profile

Immunotherapy while delaying HAART

350 CD4 threshold for starting therapy

Ageing of the PLH population

• Cardiovascular disease

• Diabetes

• Dementia

• Physical weakness– Care for elderly– Mobility

• Sensory impairment

• Living will/Funeral arrangements…

New Drugs

• Celsentri (Maraviroc) – CCR5 antagonist

• Isentress (Raltegravir) – Integrase inhibitor

• Atripula od (Tenofovir+ Emtrica +Sustiva)